Catalog No.
DVV00303
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
1.07 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY-3819253, LY-CoV555, LY3819253, CAS: 2423943-37-5
Clone ID
Bamlanivimab
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, PMID: 33475701
Bamlanivimab, PMID: 33226744
An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19, PMID: 33306087
Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients, PMID: 33177042
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19, PMID: 33113295
Antimicrobial stewardship and bamlanivimab: Opportunities for outpatient preauthorization?, PMID: 33213544
COVID-19 vaccines: The status and perspectives in delivery points of view, PMID: 33359141
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline, PMID: 33319649
Antibodies to watch in 2021, PMID: 33459118
An EUA for bamlanivimab - a monoclonal antibody for COVID-19, PMID: 33443490
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, PMID: 33356051
Bamlanivimab for Prevention of COVID-19, PMID: 34081075
Bamlanivimab Use in a Military Treatment Facility, PMID: 33993281
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, PMID: 34260849
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic, PMID: 33253920
Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community, PMID: 34430093
Etesevimab and Bamlanivimab, PMID: 33630482
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial, PMID: 34081073
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2, PMID: 34374951
Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study, PMID: 33846730
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents, PMID: 33388760
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19, PMID: 34411003
An EUA for bamlanivimab and etesevimab for COVID-19, PMID: 33830966
Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19, PMID: 34341781
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, PMID: 34250192
Bamlanivimab For Mild to Moderate COVID-19 in Kidney Transplant Recipients, PMID: 34222731
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19, PMID: 34075387
Bamlanivimab infusion experience at one academic emergency department, PMID: 34294501
Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design, PMID: 34328670
Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy, PMID: 34358400
Etesevimab, PMID: 34283469
First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID-19, PMID: 34455583
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients, PMID: 34081820
Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience, PMID: 33595145
Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, PMID: 34435337
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany, PMID: 34278371
Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient, PMID: 34009286
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting, PMID: 34258324
Consequences of rush to emergency use authorization of bamlanivimab, PMID: 34216205
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro, PMID: 33619479
Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for CNS Practice, PMID: 33793179
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro, PMID: 34074219
Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona, PMID: 34000267
Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice, PMID: 33793172
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, PMID: 34279629
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future, PMID: 34304682
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2, PMID: 34452507
Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study, PMID: 33981518
Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance, PMID: 34437928
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination, PMID: 34270919
For research use only. Not for human or drug use.
